Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Oncol., 19 June 2025

Sec. Hematologic Malignancies

Volume 15 - 2025 | https://doi.org/10.3389/fonc.2025.1641150

Correction: Efficacy and safety of pegylated interferon in the treatment of JAK2V617F-positive polycythemia vera with a dose de-escalation strategy: a single-center retrospective study

This article is a correction to:

  1. Efficacy and Safety of Pegylated Interferon in the Treatment of JAK2 V617F -Positive Polycythemia Vera with a Dose De-escalation Strategy: A Single-Center Retrospective Study

    1. Read original article
Long Chang,&#x;Long Chang1,2†Wen-Xin Li,&#x;Wen-Xin Li1,2†Hao Cai,Hao Cai1,2Jian Li,Jian Li1,2Ming-Hui Duan,*Ming-Hui Duan1,2*
  • 1Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
  • 2State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Beijing, China

A Correction on
Efficacy and safety of pegylated interferon in the treatment of JAK2V617F-positive polycythemia vera with a dose de-escalation strategy: a single-center retrospective study

By Chang L, Li W-X, Cai H, Li J and Duan M-H (2025). Front. Oncol. 15:1586839. doi: 10.3389/fonc.2025.1586839

In the published article, there was an error in the Funding statement. “The funder National High Level Hospital Clinical Research Funding 2022-PUMCH-B-047 to Ming-hui Duan” was erroneously omitted. The correct Funding statement appears below.

“This study was supported by the National High Level Hospital Clinical Research Funding 2022-PUMCH-B-047 to Ming-hui Duan. This study also received funding from Xiamen Amoytop Biotech Co., Ltd. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: polycythemia vera, pegylated interferon, JAK2v617F mutation, dose de-escalation strategy, hematological and molecular response

Citation: Chang L, Li W-X, Cai H, Li J and Duan M-H (2025) Correction: Efficacy and safety of pegylated interferon in the treatment of JAK2V617F-positive polycythemia vera with a dose de-escalation strategy: a single-center retrospective study. Front. Oncol. 15:1641150. doi: 10.3389/fonc.2025.1641150

Received: 04 June 2025; Accepted: 06 June 2025;
Published: 19 June 2025.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2025 Chang, Li, Cai, Li and Duan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Ming-Hui Duan, bWhkdWFuQHNpbmEuY29t

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.